June 5, 2020 / 10:26 AM / a month ago

BRIEF-Tetraphase - U.S. FDA Approves Co's Application For New Strength Of Xerava

June 5 (Reuters) - Tetraphase Pharmaceuticals Inc:

* TETRAPHASE PHARMACEUTICALS - ON JUNE 4 RECEIVED NOTICE THAT U.S. FDA APPROVED CO’S SUPPLEMENTAL NEW DRUG APPLICATION FOR NEW STRENGTH OF XERAVA

* TETRAPHASE - XERAVA APPROVED FOR INJECTION FOR COMPLICATED INTRA-ABDOMINAL INFECTIONS TREATMENT IN ADULT PATIENTS CONTAINING 100MG OF ERAVACYCLINE PER VIAL

* TETRAPHASE - XERAVA APPROVED AS EXTENSION OF 'IN-USE' SHELF LIFE FOR XERAVA DILUTED READY FOR INFUSION IV SOLUTION FROM 7-10 DAYS UNDER REFRIGERATED CONDITIONS Source text: (bit.ly/3cHMwT7) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below